What does Miglustat (Opfolda, Yargesa, Zavesca) do in plain English—and how does it work inside your body?
Miglustat is an FDA-regulated Glucosylceramide Synthase Inhibitor (RxNorm RxCUI 401938). Mechanistically, 12.1 Mechanism of Action Type 1 Gaucher disease is caused by a functional deficiency of glucocerebrosidase, the enzyme that mediates the degradation of the glycosphingolipid glucosylceramide. Miglustat functions as a competitive and reversible inhibitor of the enzyme glucosylceramide synthase, the initial enzyme in a series of reactions which results in the synthesis of most glycosphingolipids. [1][2].
When your doctor writes a prescription for Miglustat (RxNorm RxCUI 401938, also dispensed under brand names including Opfolda, Yargesa, Zavesca), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, 12.1 Mechanism of Action Type 1 Gaucher disease is caused by a functional deficiency of glucocerebrosidase, the enzyme that mediates the degradation of the glycosphingolipid glucosylceramide. Miglustat functions as a competitive and reversible inhibitor of the enzyme glucosylceramide synthase, the initial enzyme in a series of reactions which results in the synthesis of most glycosphingolipids. [2].
Across real-world patient logs on dotMD (93% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Miglustat tablet bottle and confirm with your pharmacist that it matches your prescribed strength (100 mg/1 Capsule, 65 mg/1 Capsule, 100mg Bottle of 90 Capsules).